ELVN trades 64.9% below Wall Street's consensus target of $76.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ELVN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Enliven Therapeutics, Inc. (ELVN) has a Wall Street consensus price target of $76.00, based on estimates from 9 covering analysts. With the stock currently trading at $46.09, this represents a potential upside of +64.9%. The company has a market capitalization of $3.29B.
Analyst price targets range from a low of $65.00 to a high of $82.00, representing a 22% spread in expectations. The median target of $78.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ELVN trades at a trailing P/E of -25.2x. Analysts expect EPS to grow -13.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KYMRKymera Therapeutics, Inc. | $9.5B | $115.47 | $136.75 | +18.4% | Buy | — | 27 |
 RVMDRevolution Medicines, Inc. | $40.6B | $190.74 | $247.00 | +29.5% | Buy | — | 24 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 AUPHAurinia Pharmaceuticals Inc. | $2.1B | $16.40 | $16.00 | -2.4% | Buy | 17.4x | 15 |
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
 ARQTArcutis Biotherapeutics, Inc. | $3.3B | $26.38 | $38.00 | +44.0% | Buy | 53.1x | 12 |
 MGNXMacroGenics, Inc. | $242M | $3.80 | $6.00 | +57.9% | Buy | — | 22 |
 PTCTPTC Therapeutics, Inc. | $5.2B | $62.34 | $105.13 | +68.6% | Buy | 49.1x | 26 |
 BCABBioAtla, Inc. | $3M | $1.74 | $250.00 | +14309.2% | Buy | — | 9 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
Quick answers to the most common questions about buying ELVN stock.
The consensus Wall Street price target for ELVN is $76, representing 64.9% upside from the current price of $46.09. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ELVN has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $76 implies 64.9% upside from current levels.
ELVN's current price is $46.09 with a consensus target of $76 (64.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $82 for ELVN, while the most conservative target is $65. The consensus of $76 represents the median expectation. These targets typically reflect 12-month expectations.
ELVN is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ELVN stock forecast based on 9 Wall Street analysts shows a consensus price target of $76, with estimates ranging from $65 (bear case) to $82 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ELVN, with a "Buy" consensus rating and $76 price target (64.9% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ELVN analyst price targets range from $65 to $82, a 22% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $76 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.